Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Inferior Vena Cava Filter Retrieval Trends: A Single Center Experience

Filip Ionescu, MD, Nwabundo Anusim, MD, Eva Ma, MD, Lihua Qu, MD MIS, Leann Blankenship, MD, Michael Stender, MD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 4690.

https://doi.org/10.1182/blood-2019-129366

Published: 2019

Journal Articles

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Carrie I Ho, MD, Hatcher J. Ballard, BS, W. Tris Arscott, MD, Mitchell E. Hughes, PharmD, Abigail Doucette, MPH, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, James N. Gerson, MD, Amit Maity, MD PhD, Stephen J. Schuster, MD, Stefan K. Barta, MD MRCP, MS, John Plastaras, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 2905.

https://doi.org/10.1182/blood-2019-124195

Published: 2019

Journal Articles

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Joanna M Rhodes, MD, Suchitra Sundaram, MD, Adam Zayac, MD, Adam J Olszewski, MD, Paolo Caimi, MD, Zachary Braunstein, MD, Jonathan E Brammer, MD, Waqas Jehangir, MD, Elvira Umyarova, MD, Sheenu Sheela, MD, Nilanjan Ghosh, MD PhD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MD MRCP, MS

Blood (2019) 134 (Supplement_1): 2854.

https://doi.org/10.1182/blood-2019-124447

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies

Vinay B Rao, Emmanuelle Belanger, PhD, Pamela C Egan, MD, Thomas W. LeBlanc, MDMA,MHS, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 384.

https://doi.org/10.1182/blood-2019-121955

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Xiaoyi Wang, MD MPH, Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J Davidoff, PhD MS, Rong Wang, PhD

Blood (2019) 134 (Supplement_1): 116.

https://doi.org/10.1182/blood-2019-126643

Published: 2019

Journal Articles

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Suchitra Sundaram, MD, Matthew Gravina, MD, Pallawi Torka, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 4058.

https://doi.org/10.1182/blood-2019-132244

Published: 2019

Journal Articles

Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial

Gregory A. Abel, MDMPH, Hajime Uno, PhD, Anna M. Tanasijevic, MPH, Zilu Zhang, MS, Tammy T Hshieh, MD MPH, Clark T Dumontier, MD, Richard Chen, BA, Lee Mozessohn, MD, Richard M. Stone, MD, Robert J. Soiffer, MD, Jane Driver, MD MPH

Blood (2019) 134 (Supplement_1): 67.

https://doi.org/10.1182/blood-2019-126158

Published: 2019

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

Peter Barth, MD, Smith Giri, MBBS, John L. Reagan, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3155.

https://doi.org/10.1182/blood-2019-121992

Published: 2019

Journal Articles

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 286.

https://doi.org/10.1182/blood-2018-99-113749

Published: 2018

Journal Articles

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Pamela C Egan, MD, Thomas W. LeBlanc, MD MA, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 829.

https://doi.org/10.1182/blood-2018-99-112692

Published: 2018

Journal Articles

Impact of Timing and Location of Goals of Care Discussions for Patients with Blood Cancers

Oreofe O. Odejide, MD, Angel M. Cronin, MS, Anays Murillo, MPH, James A. Tulsky, MD, Gregory A. Abel, MDMPH

Blood (2018) 132 (Supplement 1): 973.

https://doi.org/10.1182/blood-2018-99-112278

Published: 2018

Journal Articles

A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells

Irene Cortese, Austin John Barrett, David F. Stroncek, Steven Highfill, PhD, Erin Beck, Frances Andrada, Joan Ohayon, Jennifer Dwyer, Matthew Schindler, Georg Aue, Daniel Reich, Avindra Nath, Pawel Muranski, MD

Blood (2018) 132 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2018-99-119832

Published: 2018

Journal Articles

Influenza Vaccination Rates during the First Year after Diagnosis of Diffuse Large B Cell Lymphoma

Andres Chang, MD PhD, Jackelyn B. Payne, MPH, BS, BA, Pamela Allen, MD MSc, Jean L. Koff, MD, Rafi Ahmed, PhD, Christopher R Flowers, MD MS, Robert A Bednarczyk, PhD

Blood (2018) 132 (Supplement 1): 4820.

https://doi.org/10.1182/blood-2018-99-117168

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD

Blood (2018) 132 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2018-99-110871

Published: 2018

NARROW

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Inferior Vena Cava Filter Retrieval Trends: A Single Center Experience

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Impact of Timing and Location of Goals of Care Discussions for Patients with Blood Cancers

A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells

Influenza Vaccination Rates during the First Year after Diagnosis of Diffuse Large B Cell Lymphoma

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only